Overview

A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors

Status:
Unknown status
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose (RD) for further phase II studies, of the Galectin-1 inhibitor OTX008 given subcutaneously in patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Oncoethix GmbH